BPC-157
A synthetic pentadecapeptide fragment of a protein found in human gastric juice, widely discussed for tissue healing. Its evidence base is almost entirely preclinical — rodent and cell-culture studies — with no completed randomized human trials.
GHK-Cu
A naturally occurring copper-binding tripeptide with a topical cosmetic evidence base for skin appearance — and essentially no human injectable data.
Origin and identity
GHK-Cu (glycyl-L-histidyl-L-lysine complexed with copper) is a tripeptide identified in human plasma in the 1970s; its concentration declines with age. BPC-157 is a synthetic sequence derived from a gastric-juice protein, first studied in the 1990s. GHK-Cu is endogenous to humans; BPC-157 is not a human sequence.
Evidence
Neither compound has a completed controlled human trial for a repair indication. GHK-Cu, however, has a broader mechanistic literature and small human studies in skin and wound contexts, including topical cosmetic research. BPC-157’s base is almost entirely rodent work — tendon, ligament, and organoprotection models — and part of that literature has faced credibility scrutiny.
Mechanism
GHK-Cu’s proposed actions center on copper delivery, stimulation of collagen and glycosaminoglycan synthesis, and gene-expression shifts. BPC-157 is proposed to influence angiogenesis, fibroblast migration, and nitric-oxide signaling. The mechanisms are unrelated, and nothing in pharmacology suggests they substitute for each other.
Safety
GHK-Cu has a long topical-use history with a reassuring tolerability record in cosmetic contexts; injectable systemic data are thin. BPC-157 has no human safety database at all. For both, gray-market supply adds unverified identity and sterility risks on top.
Regulatory status
Neither is an approved injectable medicine. GHK-Cu appears in cosmetics research and specific regulated wound-care products; BPC-157 is unapproved as a drug everywhere and is explicitly flagged by some regulators as a risky research chemical.
Practical takeaway
If the question is which one has more human-adjacent data for skin, GHK-Cu is the honest answer. If the question is which one has controlled human evidence for tendon or joint repair, the honest answer is neither.
Frequently Asked Questions
Can they be combined?
No study has tested the combination. Vendor "synergy" claims are marketing language without a pharmacological or clinical basis.
Is GHK-Cu approved for wounds?
Copper-peptide dressings exist from specific manufacturers with specific formulations — that is not the same as approving bulk gray-market powder for injection.
Why is BPC-157 controversial?
Its entire effect base is preclinical, parts of its rodent literature have been questioned, and it is nonetheless widely sold with confident therapeutic claims. That gap is the controversy.
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.